For the first timehttps://www.innovationtoronto.com/wp-content/uploads/2019/10/213780_webwe4.jpg, scientists have identified a simple way that can effectively transport medication into the brain – which could lead to improved treatments for neurological and neurodegenerative diseases.
In a study published today in Nature Communications, scientists from Newcastle University, UK, have led an international team in a major breakthrough in unlocking the secrets of how medications can infiltrate the brain.
Blood capillaries in the brain are not permeable to many drugs and the majority are excluded from the brain by a protective barrier, called the blood-brain-barrier (BBB), and current treatment options are risky.
Some viruses, however, have found ways to bypass the BBB and enter the brain. To treat certain neurological and neurodegenerative diseases, medication has to use modified viruses to bypass this barrier and deliver drugs to the area.
The team has now engineered small particles, similar to the size of viruses, from a peptide that can behave like a carrier to the brain and can be packed with drugs for intravenous injection.
Professor Moein Moghimi, who led the research, said: “Crossing the blood-brain-barrier has hindered the industry from effectively addressing central nervous system diseases, including brain tumours, and many neurological diseases like Parkinson’s, Alzheimer’s and Huntington’s.
“This breakthrough – based on more than 10 years of research – has significant implications for crossing BBB and other biological barriers that have created challenges for drug delivery.
“Our breakthrough allows for minimally invasive combination delivery through an intravenous injection of various drugs, peptides and nucleic acid therapeutics to the brain.”
At present, treatment of neurological disorders involves difficulties in ‘packaging’ viruses safely and medication is usually administered by injection into the cerebrospinal fluid, which is not without risks.
The new technological breakthrough in delivering genetic materials to cells in the brain has used a peptide component from a virus that targets the brain (a bacteriophage fd). The peptide was synthesised and modified slightly, and when water was added it spontaneously formed a ‘small, hairy particle’.
Scientists found that when the developed particle was injected into a mouse model, the system targeted the brain, crossing the blood-brain-barrier, reaching neurons and microglia cells in the brain.
Professor Moghimi added: “We are very excited by our research – our delivery system is versatile and amenable to modifications, so, in principle, we can hopefully address shortfalls in drug delivery to the brain through intravenous injection.
“We have a long way to go, but we hope that our technology platform may open up many opportunities to address neurodegenerative diseases with modern therapeutics and genetic drugs.”
Through the mouse model, scientists found their technique was safe. Further research will test the technology in animal disease models in preparation for clinical trials.
Gary Leo, SMDG’s SVP of Corporate Development and former national president and CEO of the ALS Association, USA, said: “Bearing in mind the fact that neurological disorders are growing in incidence faster than any other disease class worldwide, governments will face a huge burden and increasing demands for treatment and support services.
“New knowledge is required to develop effective treatment strategies, and the new technology reported in Nature Communications is a promising achievement to fulfil these goals.”
The Latest on: Blood-brain-barrier
via Google News
The Latest on: Blood-brain-barrier
- Addressing Anti-Vaxxer Concerns Important for Nationwide Vaccinationon November 24, 2020 at 8:57 pm
There are claims of aluminium ‘nanoparticles’ in vaccines crossing the blood-brain barrier harming brain cells. Nanoparticles use in vaccines is not impossible as researchers from the University of ...
- Immune cells trained in the gut protect the brainon November 24, 2020 at 10:03 am
Researchers found that the brain’s protective membranes are guarded against microbes by immune cells that are trained in the gut. These cells produce protective antibodies whether or not an infectious ...
- Black Diamond Therapeutics Provides Update on GBM Program and Presents Pre-Clinical Data at the 2020 SNO Annual Meetingon November 19, 2020 at 11:45 pm
BDTX-1535 nominated as development candidate with IND-enabling studies underway Pre-clinical data supportnovel and differentiated approach in GBM ...
- Focused ultrasound tackles brain tumours in a myriad wayson November 18, 2020 at 1:45 am
Focused ultrasound can be used to open the blood–brain barrier, enabling delivery of drugs into the brain. (Courtesy: Kevin Van Paassen, Sunnybrook Health Sciences Centre) “Focused ultrasound is a ...
- Blood-brain barrier ‘road map’ may boost drug deliveryon November 12, 2020 at 4:00 pm
The greatest obstacle when it comes to treating cancer that has spread to the brain is the blood-brain barrier, the brain’s natural defense mechanism that is a collection of blood vessels that ...
- Glioblastoma Nanomedicine Breaks through Blood-Brain Barrier in Miceon November 11, 2020 at 11:59 pm
Researchers from the University of Michigan report they have developed a new synthetic protein nanoparticle capable of passing through the nearly impermeable blood-brain barrier (BBB) in mice that ...
- Nanotech jumps blood-brain barrier to kill cancer in miceon November 11, 2020 at 1:58 pm
A new synthetic protein nanoparticle capable of slipping past the nearly impermeable blood-brain barrier in mice could deliver cancer-killing drugs directly to malignant brain tumors, new research ...
- Bringing drugs to the brain with nanoparticles to treat neurodegenerative diseaseson November 9, 2020 at 10:52 am
Researchers have shown that nanoparticles could be used to deliver drugs to the brain to treat neurodegenerative diseases. Researchers from the Institut national de la recherche scientifique (INRS ...
- Ossianix to Present Preclinical Data Demonstrating Best-in-Class Blood Brain Barrier Delivery in Non-Human Primates by Single Domain VNAR Antibodieson November 9, 2020 at 6:03 am
"These latest results of our VNAR antibody BBB delivery are a truly exciting advancement in our quest to overcome the blood-brain barrier for CNS therapies," said Ossianix CEO Frank S. Walsh ...
- US Blood Brain Barrier Technologies Market Share, Current Trends and Research Development Report to 2025on November 2, 2020 at 10:22 pm
Nov 03, 2020 (Heraldkeepers) -- Blood Brain Barrier Technologies Market valued approximately USD xxx billion in 2017 is anticipated to grow with a healthy growth rate of more than xxx% over the ...
via Bing News